Human T-lymphotropic virus type II (HTLV-II) was initially isolated from a patient with hairy cell leukemia in the United States. Recently, it was demonstrated to be infected concomitantly with human immunodeficiency virus type-1 (HIV-1) and human T-lymphotropic virus type I (HTLV-I) in intravenous drug abusers (IVDAs) in the United States. Further more, HTLV-II was present in American intravenous drug abusers by the early 1970s and was introduced into this population before HIV-1. Moreover, HTLV-II infections have been found in the Guaymi Indians in Panama and American Indians in New Mexico. Although HTLV- II has been suggested to be related with a neurological disorder and studied for the effects on HIV-1 -induced diseases, it is not known to be associated with any specific disease, in contrast to HTLV-I.
A seroepidemiologic survey was performed to study the spread of retrovirus infections of the HTLVs and HIV in Japan, Vietnam, Thailand and India. In initial experiments, various enzyme-linked immunoassays (ELISA) for HTLV-II, that are commercially available, were used for screening assays. However, they detected false-positive in more than fifty percent of the serum specimens of Japanese hemophiliacs that had been injected non-heated and heated factor VIII or prothrombin complex concentrates, repeatedly. Then, we devised HTLV-II ELISA using the K15 peptide that is specific for HTLV-II, the combination of the ELISA test and PA test for HTLV- I were selected as a primary screening assay for seropositivity for HTLV-I / II because both tests successfully detected seropositives for HTLV-I or HTLV- II.
Serum specimens were assayed for HTLV- II infections in Japanese hemophiliacs, and blood donors in Thailand, India and Vietnam. HTLV- II infections have not been detected in the Japanese hemophiliacs or blood donors in Thailand and India. By contrast, approximately one percent of these donors exhibited seropositive for HTLV- II in South Vietnam, but none of them in North Vietnam. Further more, all these individuals seropositive for HTLV- II were detected in IVDAs that were seronegative for HIV-1 or HTLV- I. To confirm the findings, we further studied the HTLV -II infections in classified risk groups; normal healthy controls, children, pregnant women, prostitutes, IVDAs, patients under hemodialysis and hemophiliacs. Interestingly, we revealed the HTLV-II infections exclusively in 60 percent of the IVDAs in South Vietnam. The median of the age of HTLV-II infected IVDAs was 36-40 (45%). These findings show that HTLV-II infection is specifically prevalent in IVDAs in South Vietnam.
Collectively these findings show that approximately 60 percent of these IVDAs in South Vietnam (119/200) exhibited seropositive for HTLV- II, showing that HTLV- II is prevalent in IVDAs in South Vietnam.
View full abstract